Modern approaches to the treatment of congenital neutropenia




congenital neutropenia, treatment, Granulocyte colony-stimulating factor (G-CSF)


Neutropenia is common in the practice of both primary care physicians and physicians of sub-speciality. Congenital neutropenia are rare diseases; they can be both isolated independent diseases and accompany a number of other inborn errors of immunity. The clinical course of neutropenia can range from asymptomatic in patients with mild neutropenia to life-threatening infections in cases of severe neutropenia. Treatment of congenital neutropenia remains discutable to this day. The most common and accessible method of treatment of severe congenital neutropenia is granulocyte colony-stimulating factor, although it does not cure the disease and does not prevent the development of malignant transformation. On the other hand, the use of granulocyte colony-stimulating factor in the correct doses can improve the clinical course of the disease, the quality of life of patients, avoid severe septic complications. Hematopoietic stem cell transplant is an effective treatment for severe congenital neutropenia that does not respond to granulocyte colony-stimulating factor therapy. Modern methods of genetic therapy open new perspectives in the treatment of patients with severe congenital neutropenia.

No conflict of interests was declared by the author.


Badolato R, Fontana S, Notarangelo LD, Savoldi G. (2004). Congenital neutropenia: advances in diagnosis and treatment. Curr Opin Allergy Clin Immunol. 4 (6): 513-521.; PMid:15640692

Beaupain B, Leblanc T, Reman et al. (2009). Is pegfilgrastim safe and effective in congenital neutropenia? An analysis of the French Severe Chronic Neutropenia registry. Pediatr Blood Cancer. 53 (6): 1068-1073.; PMid:19618456

Bellanné-Chantelot C, Schmaltz-Panneau B, Marty C et al. (2018). Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamond-like syndrome. Blood. 132 (12): 1318-1331.; PMid:29914977 PMCid:PMC6536700

Berliner N, Horwitz M, Loughran TP. (2004). Congenital and acquired neutropenia. Hematology Am Soc Hematol Educ Program: 63-79.; PMid:15561677

Boxer LA. (2012). How to approach neutropenia. Hematology Am Soc Hematol Educ Program: 174-182.; PMid:23233578

Boyarchuk O, Balatska N, Chornomydz I. (2019). Evaluation of warning signs of primary immunodeficiencies. Pediatria Polska - Polish Journal of Paediatrics. 94 (6): 337-341.

Boyarchuk O, Dmytrash L. (2019). Clinical Manifestations in the Patients with Primary Immunodeficiencies: Data from One Regional Center. Turkish Journal of Immunology. 7 (3): 113-119.

Boyarchuk O, Kinash M, Hariyan T, Bakalyuk T. (2019). Evaluation of knowledge about primary immunodeficiencies among postgraduate medical students. Archives of the Balkan Medical Union. 54 (1): 11-19.

Boyarchuk O, Lewandowicz-Uszyńska A, Kinash M, Haliyash N, Sahal I, Kovalchuk T. (2018). Physicians' awareness concerning primary immunodeficiencies in the Ternopil Region of Ukraine. Pediatria Polska. 93 (3): 221-228.

Boyarchuk O, Volokha A, Hariyan T et al. (2019). The impact of combining educational program with the improving of infrastructure to diagnose on early detection of primary immunodeficiencies in children. Immunol Res. 67 (4-5): 390-397.; PMid:31713829

Boyarchuk O. (2021). Azithromycin and Co-Trimoxazole in Antimicrobial Prophylaxis: Special Emphasis on Primary Immunodeficiencies in Children. Bangladesh Journal of Medical Science. 20 (3): 530-538.

Chernyshova L, Volokha A, Kostyuchenko L et al. (2013). Dytiacha immunologia. Kyiv: Medytsyna: 720.

Dale DC, Cottle TE, Fier CJ et al. (2003). Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. American Journal of Hematology. 72: 82-93.; PMid:12555210

Dale DC. (2017). How I manage children with neutropenia. Br J Haematol. 178 (3): 351-363.; PMid:28419427

Deordieva E, Shvets O, Voronin K et al. (2021). Nicotinamide (vitamin B3) treatment improves response to G-CSF in severe congenital neutropenia patients. Br J Haematol. 192 (4): 788-792.; PMid:33471934

Donadieu J, Beaupain B, Fenneteau O, Bellanné-Chantelot C. (2017). Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history. Br J Haematol. 179 (4): 557-574.; PMid:28875503

Donadieu J, Beaupain B, Mahlaoui N, Bellanné-Chantelot C. (2013). Epidemiology of congenital neutropenia. Hematol Oncol Clin North Am. 27 (1): 1-17.; PMid:23351985

Fadeel B, Garwicz D, Carlsson G, Sandstedt B, Nordenskjöld M. (2021). Kostmann disease and other forms of severe congenital neutropenia. Acta Paediatr. 110 (11): 2912-2920.; PMid:34160857

Fioredda F, Iacobelli S, van Biezen A et al. (2015). Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. Blood. 126: 1885-1892.; PMid:26185129

Hariyan T, Kinash M, Kovalenko R, Boyarchuk O. (2020). Evaluation of awareness about primary immunodeficiencies among physicians before and after implementation of the educational program: A longitudinal study. PLoS One. 15 (5): e0233342.; PMid:32470021 PMCid:PMC7259605

James RM, Kinsey SE. (2006). The investigation and management of chronic neutropenia in children. Arch Dis Child. 91 (10): 852-858.; PMid:16990357 PMCid:PMC2066017

Lebel A, Yacobovich J, Krasnov T et al. (2015). Genetic analysis and clinical picture of severe congenital neutropenia in Israel. Pediatric Blood and Cancer. 62: 103-108.; PMid:25284454

Link DC. (2019). Mechanisms of leukemic transformation in congenital neutropenia. Curr Opin Hematol. 26 (1): 34-40.; PMid:30431463 PMCid:PMC6447304

Makaryan V, Kelley ML, Fletcher B, Bolyard AA, Aprikyan AA, Dale DC. (2017). Elastase inhibitors as potential therapies for ELANE‐associated neutropenia. Journal of leukocyte biology. 102 (4): 1143-1151.; PMid:28754797 PMCid:PMC5597518

Makaryan V, Zeidler C, Bolyard AA et al. (2015). The diversity of mutations and clinical outcomes for ELANE-associated neutropenia. Current Opinion in Hematology. 22: 3-11.; PMid:25427142 PMCid:PMC4380169

Morishima T, Watanabe K, Niwa A et al. (2014). Genetic correction of HAX1 in induced pluripotent stem cells from a patient with severe congenital neutropenia improves defective granulopoiesis. Haematologica. 99 (1): 19-27.; PMid:23975175 PMCid:PMC4007926

Nasri M, Ritter M, Mir P et al. (2020). CRISPR/Cas9-mediated ELANE knockout enables neutrophilic maturation of primary hematopoietic stem and progenitor cells and induced pluripotent stem cells of severe congenital neutropenia patients. Haematologica. 105 (3): 598-609.; PMid:31248972 PMCid:PMC7049355

Newburger PE, Dale DC. (2013). Evaluation and management of patients with isolated neutropenia. Seminars in hematology. 50 (3): 198-206.; PMid:23953336 PMCid:PMC3748385

Osone S, Imamura T, Fukushima-Nakase Y et al. (2016). Case reports of severe congenital neutropenia treated with unrelated cord blood transplantation with reduced-intensity conditioning. Journal of Pediatric Hematology-Oncology. 38: 49-52.; PMid:26599988

Rosenberg PS, Zeidler C, Bolyard AA et al. (2010). Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. British Journal of Haematology. 150: 196-199.; PMid:20456363 PMCid:PMC2906693

Salehi T, Fazlollahi MR, Maddah M et al. (2012). Prevention and control of infections in patients with severe congenital neutropenia; a follow up study. Iran J Allergy Asthma Immunol. 11 (1): 51-56.

Skokowa J, Dale DC, Touw IP, Zeidler C, Welte K. (2017). Severe congenital neutropenias. Nat Rev Dis Primers. 3: 17032.; PMid:28593997 PMCid:PMC5821468

Spoor J, Farajifard H, Rezaei N. (2019). Congenital neutropenia and primary immunodeficiency diseases. Crit Rev Oncol Hematol. 133: 149-162.; PMid:30661651

Tangye SG, Al-Herz W, Bousfiha A et al. (2020). Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 40 (1): 24-64.; PMid:31953710 PMCid:PMC7082301

, Touw IP. (2022). Congenital neutropenia: disease models guiding new treatment strategies. Curr Opin Hematol. 29 (1): 27-33.; PMid:34854832 PMCid:PMC8654271

Tran NT, Graf R, Wulf-Goldenberg A et al. (2020). CRISPR-Cas9-Mediated ELANE Mutation Correction in Hematopoietic Stem and Progenitor Cells to Treat Severe Congenital Neutropenia. Mol Ther. 28 (12): 2621-2634.; PMid:32822592 PMCid:PMC7704744

Tulpule A, Kelley JM, Lensch MW et al. (2013). Pluripotent stem cell models of Shwachman-Diamond syndrome reveal a common mechanism for pancreatic and hematopoietic dysfunction. Cell Stem Cell. 12 (6): 727-736.; PMid:23602541 PMCid:PMC3755012

Walkovich K, Connelly JA. (2019). Congenital Neutropenia and Rare Functional Phagocyte Disorders in Children. Hematol Oncol Clin North Am. 33 (3): 533-551.; PMid:31030818